Safety of long-acting β-agonists: urgent need to clear the air remains

The introduction of long-acting β-agonist (LABA) drugs in the 1990s was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life 1, 2. There were also potential safety advantages due to the twice daily, fixed dose usage, which reduced the risk of overuse of β-agonist therapy in the situation of severe exacerbations. The subsequent introduction of the combination of LABA/inhaled corticosteroid (ICS) products had the added potential value of ensuring that the patient received concomitant ICS therapy while improving compliance with ICS therapy 3, 4. However, concerns about the possible risks associated with LABA therapy were raised soon after their introduction into clinical practice, with the evidence that regular LABA use had the potential to reduce bronchodilator sensitivity to β-agonists 5, 6 and induce tolerance to their bronchoprotective effects 7, which may not be restored by concurrent use of ICS 8. It also became apparent that patients using LABAs may be at risk of severe exacerbations if the symptom control achieved with LABA use led to a discontinuation of ICS therapy 9. There were also concerns about a potential risk of mortality from the Salmeterol Nationwide Surveillance Study 10. In this UK-based study of >25,000 subjects, there was a nonsignificant three-fold increased risk of asthma death in subjects treated with salmeterol compared with regular salbutamol; however, there was no increase in hospital admissions or life-threatening events. This led to the USA-based Salmeterol Multicenter Asthma Research Trial (SMART), a placebo-controlled study of the safety of salmeterol in adults with unstable asthma 11. The trial was stopped after an interim analysis of 26,000 subjects because it showed a statistically significant, four-fold increase in asthma mortality with salmeterol. Unfortunately, due to low …

[1]  F. Radner,et al.  Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials , 2009, European Respiratory Journal.

[2]  M. Weatherall,et al.  The risk of asthma mortality with inhaled long acting β-agonists , 2008, Postgraduate Medical Journal.

[3]  S. Yancey,et al.  Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[5]  S. Willsie Meta-Analysis: Effect of Long-Acting β-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths , 2007 .

[6]  Alan Kaplan,et al.  Review of 'Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.' Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Ann Intern Med 2006;144:904-12. , 2006, Primary care respiratory journal : journal of the General Practice Airways Group.

[7]  R. Lipchik Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences , 2006, Evidence-based medicine.

[8]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[9]  F. Martinez Safety of long-acting beta-agonists--an urgent need to clear the air. , 2005, The New England journal of medicine.

[10]  M. Ní Chróinín,et al.  Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. , 2005, The Cochrane database of systematic reviews.

[11]  M. Ní Chróinín,et al.  Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. , 2005, The Cochrane database of systematic reviews.

[12]  J. C. Carranza Rosenzweig,et al.  Adherence to asthma controller medication regimens. , 2005, Respiratory medicine.

[13]  B. Butland,et al.  Bronchodilator treatment and deaths from asthma: case-control study , 2004, BMJ : British Medical Journal.

[14]  J. C. Carranza Rosenzweig,et al.  Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. , 2004, The Journal of allergy and clinical immunology.

[15]  British guideline on the management of asthma. , 2003, Thorax.

[16]  D. Yates,et al.  An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. , 1996, American journal of respiratory and critical care medicine.

[17]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[18]  H. Nelson β-Adrenergic Bronchodilators , 1995 .

[19]  B. Lipworth,et al.  Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients , 1995, The Lancet.

[20]  B. Lipworth,et al.  Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. , 1994, The American journal of medicine.

[21]  A. Zwinderman,et al.  Long-Term Effects of a Long-acting ??2-Adrenoceptor Agonist, Salmeterol, on Airways Hyperresponsiveness in Patients with Mild Asthma , 1993 .

[22]  W. Castle,et al.  Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. , 1993, BMJ.

[23]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[24]  N. Pearce,et al.  Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. , 1992, International journal of epidemiology.

[25]  S. Larsson,et al.  Inhaled formoterol during one year in asthma: a comparison with salbutamol. , 1991, The European respiratory journal.

[26]  K. Chung,et al.  Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma. , 1991, The European respiratory journal.

[27]  R. Beaglehole,et al.  A case-control study of deaths from asthma. , 1986, Thorax.